Starling Oncology (STLN)

Generated: November 14, 2026

Red Dot

Statistics

Metric	Value
Last Close	$3.50
Blended Price Target	6.00
Blended Margin of Safety	71.3% Undervalued
Rule of 40 (Next)	62.2%
Rule of 40 (Current)	59.8%
FCF-ROIC	28.8%
Sales Growth Next Year	33.4%
Sales Growth Current Year	31.0%
Sales 3-Year Avg	26.0%
Industry	Medical Care Facilities

Analysis

Starling Oncology appears to be a specialized healthcare-services business with a credible growth runway, but its durability depends more on execution and payer economics than on a conventional recurring-revenue model. The company provides oncology care through employed and affiliated clinicians, clinics, clinical trials, transfusions, and value-based arrangements, giving it several avenues to expand beyond fee-for-service medicine.^[3]

The business has meaningful operating relevance in a fragmented community-oncology market, but its moat is not yet clearly impregnable. Clinical expertise, payer relationships, patient scale, and physician networks can reinforce one another, while reimbursement changes and competition from hospitals, independent practices, and other oncology platforms remain substantial constraints. Leadership appears domain-focused and capable of building a scaled platform, though the public record reviewed here does not establish enough evidence to call the company exceptionally durable or founder-led.^[3]^[8]

What the Company Does

Starling Oncology delivers specialized cancer care in community settings. It coordinates diagnosis, treatment, supportive services, clinical trials, transfusions, and related care through more than 400 employed and network clinicians and over 100 clinics and network locations across five states.^[3] It makes money primarily by providing medical services and managing oncology care for patients covered by commercial insurers, government programs, and value-based contracts.

The company does not disclose a sufficiently detailed, current revenue-segment percentage breakdown in the available materials. Qualitatively, revenue appears to combine traditional clinical-care reimbursement with value-based arrangements and ancillary oncology services. The mix therefore reflects both patient volume and the economics of drugs, procedures, contracts, and care-management programs rather than a single standardized product line.^[3]^[8]

Revenue Recurrence & Predictability

Revenue is primarily transactional and contractual rather than subscription-based. Each patient encounter, treatment course, procedure, drug administration, or reimbursable service generates activity-based revenue, while value-based contracts can add recurring contractual relationships with payers.

That structure offers some predictability because cancer treatment often involves prolonged care pathways and payer relationships can persist over time. However, revenue remains exposed to patient mix, treatment intensity, reimbursement rates, authorization decisions, contract renewals, and the timing of services. The available current disclosures do not provide a reliable percentage for recurring or highly predictable revenue, so predictability should be viewed as moderate rather than comparable to software or other subscription businesses.^[3]^[5]

Revenue Growth Durability

Starling has room to expand because community oncology remains a large, fragmented healthcare category, and the company currently serves a population of approximately 2.1 million patients across a relatively limited geographic footprint.^[3] Its principal growth levers are adding clinics and clinicians, expanding payer relationships, increasing patient access, broadening clinical-trial participation, and capturing more services within existing care pathways.

Structural demand is supported by an aging population, rising cancer incidence, and continued movement toward lower-cost outpatient and community care. Against that, growth can be constrained by oncologist recruitment, clinic operating complexity, payer pressure, reimbursement changes, and the capital required to build or integrate locations. Above-market growth is plausible for several years if the platform scales efficiently, but it is not assured: expansion must translate into productive clinicians, strong local referrals, and acceptable contract economics.

Economic Moat

The company’s most credible advantages are specialized clinical knowledge, physician and payer relationships, local referral networks, and accumulated data from coordinating cancer care. These assets can improve treatment consistency, support value-based contracting, and make the platform more useful to payers seeking lower-cost oncology delivery.

The moat is more operational and relationship-based than technology-driven. Scale across clinics may improve purchasing, care coordination, and clinical-trial capabilities, while integrated workflows can raise switching costs for physicians and patients. Yet hospitals, large oncology groups, and other physician platforms can replicate many of these features. The moat could widen if Starling demonstrates superior outcomes and payer savings, but it could narrow if reimbursement becomes more standardized or competitors gain greater local density.

Management & Leadership

Starling is led by Daniel Virnich, MD, who is identified in the company’s current investor materials and earnings release as a senior executive and physician leader.^[3]^[8] The available sources do not establish that the company is founder-led, nor do they provide enough current detail to assess his full tenure and operating track record confidently.

Recent SEC materials show insider ownership filings, but the reviewed search results do not provide a reliable aggregate insider-ownership percentage.^[1]^[9] Capital allocation appears focused on expanding and operating the care platform rather than on financial engineering. The key leadership test is whether management can grow locations and contracts while maintaining clinical quality, clinician retention, and disciplined reimbursement economics.

Key Risks

Payer and regulatory risk is central. Changes in Medicare, commercial reimbursement, drug economics, value-based contracting, or authorization rules could reduce the revenue or profitability associated with particular treatments. Oncology care also carries substantial compliance and documentation requirements, making operational mistakes potentially costly.

Execution risk is equally significant. Recruiting oncologists and specialized staff, integrating clinics, maintaining consistent care standards, and converting patient access into productive volume are difficult across multiple states. Competition from hospitals, independent practices, and larger oncology networks could pressure referrals, clinician retention, and contract terms.

The model also faces technology and concentration risks. Clinical software, analytics, and care-coordination tools must work reliably without compromising patient privacy or safety. The available materials do not establish a current customer-concentration percentage, but dependence on major payers, referral sources, or a limited number of markets could make results vulnerable to contract losses or local competitive shifts.

Sources

Featured in GreenDot Stocks Analysis

GreenDot Stocks Screen Update — Week of November 14, 2026 November 14, 2026